Weighted Average Number of Shares Outstanding, Basic of Enliven Therapeutics, Inc. from 30 Jun 2021 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Enliven Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Jun 2021 to 31 Dec 2025.
  • Enliven Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 56,664,226, a 20% increase year-over-year.
  • Enliven Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 56,664,226, a 20% increase from 2024.
  • Enliven Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 47,072,532, a 32% increase from 2023.
  • Enliven Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 35,546,215, a 1038% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Enliven Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 56,664,226 +9,591,694 +20% 01 Oct 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
Q3 2025 62,093,795 +13,826,337 +29% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 52,105,052 +4,030,017 +8.4% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 50,051,283 +8,005,675 +19% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 47,072,532 +11,526,317 +32% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
Q3 2024 48,267,458 +7,236,584 +18% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 48,075,035 +7,114,011 +17% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 42,045,608 +1,084,584 +2.6% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 35,546,215 +32,421,941 +1038% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 41,030,874 +37,802,182 +1171% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 40,961,024 +37,857,050 +1220% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 40,961,024 +38,084,245 +1324% 01 Jan 2023 31 Mar 2023 10-Q 13 Aug 2024 2024 Q2
Q4 2022 3,124,274 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 3,228,692 -21,669,654 -87% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 3,103,974 -14,611,500 -82% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 2,876,779 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 24,898,346 01 Jul 2021 30 Sep 2021 10-Q 25 Oct 2022 2022 Q3
Q2 2021 17,715,474 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2

Enliven Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 56,664,226 +9,591,694 +20% 01 Jan 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
2024 47,072,532 +11,526,317 +32% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
2023 35,546,215 +32,421,941 +1038% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 3,124,274 +818,164 +35% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 2,306,110 01 Jan 2021 31 Dec 2021 8-K 23 Jun 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.